{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:44:09Z","timestamp":1792449849889,"version":"4.5.0"},"reference-count":87,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1016\/j.jsbmb.2013.09.008","type":"journal-article","created":{"date-parts":[[2013,10,29]],"date-time":"2013-10-29T04:47:57Z","timestamp":1383022077000},"page":"155-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":657,"special_numbering":"C","title":["Prevention and treatment of postmenopausal osteoporosis"],"prefix":"10.1016","volume":"142","author":[{"given":"Sri Harsha","family":"Tella","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Christopher","family":"Gallagher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jsbmb.2013.09.008_bib0005","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1002\/jbmr.5650110802","article-title":"Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis","volume":"11","author":"Pacifici","year":"1996","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0010","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1359\/jbmr.1998.13.5.763","article-title":"A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men","volume":"13","author":"Riggs","year":"1998","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0015","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1359\/jbmr.2000.15.1.2","article-title":"The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption","volume":"15","author":"Hofbauer","year":"2000","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0020","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.130200197","article-title":"Estrogens suppress RANK ligand induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression","volume":"97","author":"Shevde","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"September (7672)","key":"10.1016\/j.jsbmb.2013.09.008_bib0025","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(70)91344-9","article-title":"Marshall DH effect of age on calcium absorption","volume":"2","author":"Bullamore","year":"1970","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0030","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1001\/jama.1941.02820220007002","article-title":"Postmenopausal osteoporosis","volume":"116","author":"Albright","year":"1941","journal-title":"JAMA"},{"issue":"October (10)","key":"10.1016\/j.jsbmb.2013.09.008_bib0035","doi-asserted-by":"crossref","first-page":"4954","DOI":"10.1210\/jc.2004-0434","article-title":"Endogenous levels of serum estradiol and sex hormone binding globulin determine bone mineral density, bone remodeling, the rate of bone loss, and response to treatment with estrogen in elderly women","volume":"89","author":"Rapuri","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0040","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1056\/NEJM199809103391104","article-title":"Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group","volume":"339","author":"Cummings","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.jsbmb.2013.09.008_bib0045","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/jbmr.534","article-title":"Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN)","volume":"27","author":"Greendale","year":"2012","journal-title":"J. Bone Miner. Res."},{"issue":"September (9)","key":"10.1016\/j.jsbmb.2013.09.008_bib0050","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1359\/jbmr.1999.14.9.1614","article-title":"Markers of bone turnover predict postmenopausal forearm bone loss over 4 years: the OFELY study","volume":"14","author":"Garnero","year":"1999","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0055","unstructured":"World Health Organization Collaborating Centre for Metabolic Bone Diseases. FRAXA WHO Fracture Risk Assessment Tool. Available at: http:\/\/www.shef.ac.uk\/FRAX\/ (accessed 28.10.09)."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0060","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1359\/jbmr.2003.18.11.1947","article-title":"For the study of osteoporotic fractures research group. BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures","volume":"18","author":"Stone","year":"2003","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0065","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1001\/jama.286.22.2815","volume":"286","author":"Siris","year":"2001","journal-title":"JAMA"},{"issue":"April (8)","key":"10.1016\/j.jsbmb.2013.09.008_bib0070","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1001\/archinte.166.8.869","article-title":"Effects of calcium supplementation on clinical fracture and bone structure: results of a 5-year, double-blind, placebo-controlled trial in elderly women","volume":"166","author":"Prince","year":"2006","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0075","doi-asserted-by":"crossref","first-page":"c3691","DOI":"10.1136\/bmj.c3691","article-title":"Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis","volume":"341","author":"Bolland","year":"2010","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.jsbmb.2013.09.008_bib0080","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1007\/s001980200061","article-title":"Risedronate reduces the risk of first vertebral fracture in osteoporotic women","volume":"13","author":"Heaney","year":"2002","journal-title":"Osteoporos. Int."},{"issue":"3","key":"10.1016\/j.jsbmb.2013.09.008_bib0085","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0090","first-page":"321","article-title":"Group for the women's health initiative investigators","volume":"288","author":"Writing","year":"2002","journal-title":"JAMA"},{"issue":"September (9)","key":"10.1016\/j.jsbmb.2013.09.008_bib0095","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.2105\/AJPH.2013.301295","article-title":"The mortality toll of estrogen avoidance: an analysis of excess deaths among hysterectomized women aged 50 to 59 years","volume":"103","author":"Sarrel","year":"2013","journal-title":"Am. J. Public Health"},{"issue":"September (1)","key":"10.1016\/j.jsbmb.2013.09.008_bib0100","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.maturitas.2013.05.018","article-title":"Oral estradiol and dydrogesterone combination therapy in postmenopausal women: review of efficacy and safety","volume":"76","author":"Stevenson","year":"2013","journal-title":"Maturitas"},{"issue":"August (4)","key":"10.1016\/j.jsbmb.2013.09.008_bib0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1210\/er.2001-5002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. V. Meta-analysis of the efficacy of hormone replacement therapy in treating and preventing osteoporosis in postmenopausal women","volume":"23","author":"Wells","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0110","series-title":"Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism","first-page":"327","article-title":"Effect of estrogen on bone","author":"Gallagher","year":"2006"},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0115","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.287.20.2668","article-title":"Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women","volume":"287","author":"Lindsay","year":"2002","journal-title":"JAMA"},{"issue":"September (3)","key":"10.1016\/j.jsbmb.2013.09.008_bib0120","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.fertnstert.2009.05.094","article-title":"Endometrial effects of a tissue selective estrogen complex containing bazedoxifene\/conjugated estrogens as a menopausal therapy","volume":"92","author":"Pickar","year":"2009","journal-title":"Fertil. Steril."},{"issue":"June (22)","key":"10.1016\/j.jsbmb.2013.09.008_bib0125","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1001\/jama.285.22.2891","article-title":"Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials","volume":"285","author":"Torgerson","year":"2001","journal-title":"JAMA"},{"issue":"13","key":"10.1016\/j.jsbmb.2013.09.008_bib0130","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1001\/jama.290.13.1729","article-title":"Women's health initiative investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the women's health initiative randomized trial","volume":"290","author":"Cauley","year":"2003","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jsbmb.2013.09.008_bib0135","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1359\/jbmr.060312","article-title":"Women's health initiative investigators. Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial","volume":"21","author":"Jackson","year":"2006","journal-title":"J. Bone Miner. Res."},{"issue":"August (8)","key":"10.1016\/j.jsbmb.2013.09.008_bib0140","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1210\/jcem.86.8.7703","article-title":"Combination treatment with estrogen and calcitriol in the prevention of age-related bone loss","volume":"86","author":"Gallagher","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"May (19)","key":"10.1016\/j.jsbmb.2013.09.008_bib0145","doi-asserted-by":"crossref","first-page":"2525","DOI":"10.1001\/jama.289.19.2525","article-title":"Combination therapy with hormone replacement and alendronate for prevention of bone loss in elderly women: a randomized controlled trial","volume":"289","author":"Greenspan","year":"2003","journal-title":"JAMA"},{"issue":"November (11)","key":"10.1016\/j.jsbmb.2013.09.008_bib0150","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.1359\/jbmr.070707","article-title":"Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women","volume":"22","author":"Huang","year":"2007","journal-title":"J. Bone Miner. Res."},{"issue":"May (5)","key":"10.1016\/j.jsbmb.2013.09.008_bib0155","first-page":"1890","article-title":"Calcium potentiates the effect of estrogen and calcitonin on bone mass: review and analysis","volume":"86","author":"Nieves","year":"2001","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"January (1)","key":"10.1016\/j.jsbmb.2013.09.008_bib0160","first-page":"18","article-title":"Effects of alendronate and hormone replacement therapy, alone and in combination, on bone mass and markers of bone turnover in elderly women with osteoporosis","volume":"67","author":"Evi\u00f6","year":"1998","journal-title":"Am. J. Clin. Nutr."},{"issue":"February (2)","key":"10.1016\/j.jsbmb.2013.09.008_bib0165","first-page":"626","article-title":"Effect of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women","volume":"89","author":"Harris","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"3","key":"10.1016\/j.jsbmb.2013.09.008_bib0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex of bazedoxifene\/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women","volume":"93","author":"Lindsay","year":"2009","journal-title":"Fertil. Steril."},{"issue":"November-December (6 (Pt 1))","key":"10.1016\/j.jsbmb.2013.09.008_bib0175","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1097\/01.GME.0000123641.76105.B5","article-title":"Changes in bone density and turnover after alendronate or estrogen withdrawal","volume":"11","author":"Wasnich","year":"2004","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0180","unstructured":"R. Karim, R.M. Dell, D.F. Greene, W.J. Mack, et al., Hip fracture in postmenopausal women after cessation of hormone therapy: results from a prospective study in a large health management organization."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0185","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1056\/NEJMoa030808","article-title":"Estrogen plus progestin and the risk of coronary heart disease","volume":"349","author":"Manson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0190","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM199109123251102","article-title":"Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses\u2019 health study","volume":"325","author":"Stampfer","year":"1991","journal-title":"N. Engl. J. Med."},{"issue":"35","key":"10.1016\/j.jsbmb.2013.09.008_bib0195","first-page":"44","article-title":"Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation","volume":"15","author":"Grodstein","year":"2006","journal-title":"J. Womens Health (Larchmt)"},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0200","doi-asserted-by":"crossref","first-page":"4879","DOI":"10.1210\/jc.2003-031672","article-title":"Prevention of postmenopausal bone loss: six-year results from the early postmenopausal intervention cohort study","volume":"89","author":"McClung","year":"2004","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0205","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1080\/13697130500118126","article-title":"Risedronate prevents bone loss in early postmenopausal women: a prospective randomized, placebocontrolled trial","volume":"8","author":"Hooper","year":"2005","journal-title":"Climacteric"},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0210","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up","volume":"83","author":"Mortensen","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0215","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.0301202","article-title":"Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis","volume":"19","author":"McClung","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0220","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1046\/j.1365-2796.2003.01174.x","article-title":"Oral weekly ibandronate prevents bone loss in postmenopausal women","volume":"254","author":"Tanko","year":"2003","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0225","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1097\/AOG.0b013e3181bdce0a","article-title":"Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial","volume":"114","author":"McClung","year":"2009","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0230","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Fracture Intervention Trial Research Group. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0235","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0240","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Vertebral Efficacy With Risedronate Therapy (VERT) study group. Effects of risedronate treatment on vertebral and non- vertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0245","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos. Int."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0250","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.jsbmb.2013.09.008_bib0255","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/jbmr.1494","article-title":"The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)","volume":"27.","author":"Black","year":"2012","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0260","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or inter- mittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0265","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Hip intervention program study group. Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0270","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research","volume":"22","author":"Khosla","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0275","unstructured":"D.L. Diab, N.B. Watts, Use of drug holidays in women taking bisphosphonates. NAMS practice pearl."},{"issue":"9","key":"10.1016\/j.jsbmb.2013.09.008_bib0280","doi-asserted-by":"crossref","first-page":"619","DOI":"10.3949\/ccjm.78a.11022","article-title":"What is the optimal duration of bisphosphonate therapy?","volume":"78","author":"Susan","year":"2011","journal-title":"Clevel. Clin. J. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0285","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1210\/er.2001-4002","article-title":"Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0290","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1001\/archinte.160.22.3444","article-title":"Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials","volume":"160","author":"Johnston","year":"2000","journal-title":"Arch. Intern. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0295","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.GME.0000058772.59606.2A","article-title":"Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years","volume":"10","author":"Jolly","year":"2003","journal-title":"Menopause"},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0300","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the more randomized trial. Multiple outcomes of raloxifene evaluation","volume":"281","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.jsbmb.2013.09.008_bib0305","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1359\/jbmr.071206","article-title":"Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study","volume":"23","author":"Miller","year":"2008","journal-title":"J. Bone Miner. Res."},{"issue":"January (1)","key":"10.1016\/j.jsbmb.2013.09.008_bib0310","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00198-011-1691-1","article-title":"Sustained efficacy and safety of bazedoxifene in preventing fractures in postmenopausal women with osteoporosis: results of a 5-year, randomized, placebo-controlled study","volume":"23","author":"Silverman","year":"2012","journal-title":"Osteoporos. Int."},{"issue":"February (2)","key":"10.1016\/j.jsbmb.2013.09.008_bib0315","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00198-010-1259-5","article-title":"Efficacy and safety of bazedoxifene in postmenopausal Asian women","volume":"22","author":"Xu","year":"2011","journal-title":"Osteoporos. Int."},{"issue":"February (8)","key":"10.1016\/j.jsbmb.2013.09.008_bib0320","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1056\/NEJMoa0808692","article-title":"Lasofoxifene in postmenopausal women with osteoporosis","volume":"362","author":"Cummings","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0325","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis","volume":"361","author":"Cummings","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0330","doi-asserted-by":"crossref","DOI":"10.1210\/jc.2013-1597","article-title":"The effect of 3 or 6 years of denosumab exposure in women with postmenopausal osteoporosis: results from the freedom extension","author":"Bone","year":"2013","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"September (4)","key":"10.1016\/j.jsbmb.2013.09.008_bib0335","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am. J. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0345","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0350","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-146-5-200703060-00005","article-title":"Effect of recombinant human parathyroid hormone (1\u201384) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial","volume":"146","author":"Greenspan","year":"2007","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0355","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1359\/jbmr.081215","article-title":"Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS)","volume":"24","author":"Eastell","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0360","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/S0140-6736(97)02342-8","article-title":"Randomised controlled study of effect of parathyroid hormone on vertebral-bone mass and fracture incidence among postmenopausal women on oestrogen with osteoporosis","volume":"350","author":"Lindsay","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0365","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0370","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0375","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1\u201384) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"July (9886)","key":"10.1016\/j.jsbmb.2013.09.008_bib0380","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0140-6736(13)60856-9","article-title":"Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial","volume":"382","author":"Tsai","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0385","unstructured":"M.R. McClung, A. Balske, D.E. Burgio, et al., Treatment of postmenopausal osteoporosis with delayed-release risedronate 35mg weekly for 2 years."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0390","unstructured":"N. Binkley, M. Bolognese, A. Sidorowicz-Bialynicka, A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0395","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1359\/jbmr.081206","article-title":"Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis","volume":"24","author":"Li","year":"2009","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0400","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1210\/jc.2004-2126","article-title":"Effect of L-000845704, an alphaVbeta3 integrin antagonist, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women","volume":"90","author":"Murphy","year":"2005","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0405","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1359\/jbmr.091035","article-title":"Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density","volume":"25","author":"Bone","year":"2010","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0410","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/jbmr.341","article-title":"Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the ocean study","volume":"26","author":"Eastell","year":"2011","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0415","series-title":"Institute of Medicine 2011 Dietary reference intakes for calcium and vitamin D","year":"2013"},{"issue":"6","key":"10.1016\/j.jsbmb.2013.09.008_bib0420","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1002\/jbmr.5650020605","article-title":"Total Bone Calcium in Normal Women: Effect of Age and Menopause Status","volume":"2","author":"Gallagher","year":"2011","journal-title":"J. Bone Min Res."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0425","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1007\/s001980170006","volume":"12","author":"Kanis","year":"2001","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0430","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporos Int."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0435","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1056\/NEJM199503233321202","volume":"332","author":"Cummings","year":"1995","journal-title":"N engl J Med."},{"key":"10.1016\/j.jsbmb.2013.09.008_bib0440","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1210\/er.2001-9002","volume":"23","author":"Cranney","year":"2002","journal-title":"Endocr Rev."}],"container-title":["The Journal of Steroid Biochemistry and Molecular Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076013001829?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960076013001829?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T23:41:59Z","timestamp":1760744519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960076013001829"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":87,"alternative-id":["S0960076013001829"],"URL":"https:\/\/doi.org\/10.1016\/j.jsbmb.2013.09.008","relation":{},"ISSN":["0960-0760"],"issn-type":[{"value":"0960-0760","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevention and treatment of postmenopausal osteoporosis","name":"articletitle","label":"Article Title"},{"value":"The Journal of Steroid Biochemistry and Molecular Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsbmb.2013.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}